China Health Industries Holdings, Inc.: M&A transaction — China Health sells subsidiary to Chairman Xin Sun for 594k shares and $6k cash

China Health Industries Holdings, Inc.

On July 11, 2024, China Health closed the sale of 100% of Harbin Humankind Biology Technology to Chairman/CEO Xin Sun (99%) and his sister Liyuan Sun (1%).
Consideration: $594,000 paid via transfer of 594,000 shares of CHHE common stock (valued at $1.00/share) from Xin Sun; $6,000 cash from Liyuan Sun.
The subsidiary Humankind was previously wholly owned by China Health HK; its assets were transferred to another subsidiary (Hankang) prior to the sale.
This is a related-party transaction; no valuation or financial details of Humankind provided.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.7

China Health Industries Holdings, Inc. completed a disposition involving Mr. Xin Sun and Ms. Liyuan Sun for USD 600,000.

Action: disposition
Counterparty: Mr. Xin Sun and Ms. Liyuan Sun
Consideration: USD 600,000

Exact text from the filing

China Health HK agreed to transfer to Mr. Xin Sun 99% and Ms. Liyuan Sun 1% of the equity interests of Harbin Humankind Biology Technology Co., Limited. (“Humankind”), for a consideration of USD 594,000 and USD 6,000 respectively, totaling USD 600,000

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001213900-24-062025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.